CPT code 90396 designates the supply of intramuscular human varicella–zoster immune globulin for prevention or augmentation of immunity against chickenpox. This code captures a specific biologic prophylactic product used in clinical circumstances where passive immunization is indicated. Nationally, accurate reporting of this code matters for tracking use of immune globulins, ensuring appropriate coverage, and aligning billing with clinical guidelines for post-exposure or pre-exposure prophylaxis.

Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise description of the clinical context for 90396, typical sites of service, and the service type. The analysis covers payer coverage patterns and coding benchmarks where available, notes common billing modifiers used with this service, and highlights policy considerations relevant to reimbursement and documentation. Where payers have specific coverage rules or prior authorization requirements, those will be summarized to clarify administrative expectations.

This national-level summary is intended for billing staff, clinicians, and policy analysts who require a clear, practical reference for coding and documenting intramuscular varicella–zoster immune globulin supply and administration under CPT code 90396.